Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Breast 2Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 125Neoplasm Metastasis 17Ovarian Neoplasms 12Endometrial Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Hereditary Sensory and Autonomic Neuropathies 5Colorectal Neoplasms 5Advanced Breast Cancer 5Squamous Cell Carcinoma of Head and Neck 4Stomach Neoplasms 3Recurrence 3Neoplasms by Site 3Head and Neck Neoplasms 3Carcinoma, Lobular 3Breast Diseases 3Breast Cancer Metastatic 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Multiple Endocrine Neoplasia Type 1 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumors 2Urologic Neoplasms 1Urogenital Neoplasms 1

Interventions

Paclitaxel 6pembrolizumab 3Cisplatin 3Carboplatin 3Biopsy 3adavosertib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Doxorubicin 2ulixertinib 1tucatinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1sacituzumab govitecan 1relugolix 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1niraparib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Neoplasms × Fulvestrant × 1 year × Clear all
NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio, Inc

Phase 1 Active not recruiting
134 enrolled
BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡